OBJECTIVES: This study aims to further evaluate the impact of family history of primary movement disorders (FHpMD) and a candidate genetic variant on risk of antipsychotic-induced extrapyramidal symptoms (EPS). METHODS: We examined 156 (76 men) inpatients receiving antipsychotics for EPS and FHpMD stratified by patient characteristics. The genetic analysis included genotyping of a multiallelic dinucleotide polymorphism in the ATP1A3 gene. RESULTS: EPS lifetime prevalence was 69% and more frequent in the presence of FHpMD (p = 0.052), particularly in patients younger than 60 years (p = 0.012) and with acute dystonic reactions. The ATP1A3 polymorphism showed an allele length-dependent association with parkinsonism (p=0.019 uncorrected, p=0.057 corrected) exclusively. Carriers of the shortest allele had a 7.7-fold increased risk for parkinsonism. CONCLUSIONS: The association of FHpMD and EPS may be linked to the EPS subtype and age of the patient. A common ATP1A3 genomic variation may represent a susceptibility factor for the risk for antipsychotic-induced parkinsonism in an allele-dependent manner.
OBJECTIVES: This study aims to further evaluate the impact of family history of primary movement disorders (FHpMD) and a candidate genetic variant on risk of antipsychotic-induced extrapyramidal symptoms (EPS). METHODS: We examined 156 (76 men) inpatients receiving antipsychotics for EPS and FHpMD stratified by patient characteristics. The genetic analysis included genotyping of a multiallelic dinucleotide polymorphism in the ATP1A3 gene. RESULTS:EPS lifetime prevalence was 69% and more frequent in the presence of FHpMD (p = 0.052), particularly in patients younger than 60 years (p = 0.012) and with acute dystonic reactions. The ATP1A3 polymorphism showed an allele length-dependent association with parkinsonism (p=0.019 uncorrected, p=0.057 corrected) exclusively. Carriers of the shortest allele had a 7.7-fold increased risk for parkinsonism. CONCLUSIONS: The association of FHpMD and EPS may be linked to the EPS subtype and age of the patient. A common ATP1A3 genomic variation may represent a susceptibility factor for the risk for antipsychotic-induced parkinsonism in an allele-dependent manner.
Authors: S J Pittock; C Joyce; V O'Keane; B Hugle; M O Hardiman; F Brett; A J Green; D E Barton; M D King; D W Webb Journal: Neurology Date: 2000-10-10 Impact factor: 9.910
Authors: Moon S Won; Ania Mikos; Mary Hurd; Hubert Fernandez; Thomas Eskin; Janet Romrell; Michael S Okun Journal: Neurocase Date: 2008 Impact factor: 0.881
Authors: Anne Karow; Joerg Czekalla; Ralf W Dittmann; Alexander Schacht; Thomas Wagner; Martin Lambert; Benno G Schimmelmann; Dieter Naber Journal: J Clin Psychiatry Date: 2007-01 Impact factor: 4.384
Authors: Ismail Al-Janabi; Maria J Arranz; Alexandra I F Blakemore; Pilar A Saiz; Margaret T Susce; Paul E A Glaser; Daniel Clark; Jose de Leon Journal: Psychiatr Genet Date: 2009-12 Impact factor: 2.458
Authors: Maju Mathews; Isaac Nuamah; Adam J Savitz; David W Hough; Dean Najarian; Edward Kim; Srihari Gopal Journal: Neuropsychiatr Dis Treat Date: 2018-10-25 Impact factor: 2.570
Authors: Antonio Drago; Ina Giegling; Martin Schäfer; Annette M Hartmann; Hans-Jürgen Möller; Diana De Ronchi; Hans H Stassen; Alessandro Serretti; Dan Rujescu Journal: PLoS One Date: 2012-10-15 Impact factor: 3.240